{"schema_version":"secwatch.filing_event.v1","accession":"0000950103-24-005064","form_type":"8-K","ticker":"ADCT","cik":"0001771910","company_name":"ADC Therapeutics SA","filed_at":"2024-04-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.997263+00:00","generated_at":"2026-06-04T01:01:09.624552+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"low","headline":"ADC Therapeutics presents exatecan-based ADC platform at virtual investor event","bullets":["CEO Ameet Mallik and CSO Patrick van Berkel to present updates on novel exatecan-based ADC platform.","Agenda includes business update, research strategy, platform, and lead candidates.","Presentation made available on April 9, 2024, with live Q&A session to follow.","No financial results or material non-public information disclosed in the filing."],"urls":{"canonical":"https://secwatch.observer/filing/0000950103-24-005064","json":"https://secwatch.observer/filing/0000950103-24-005064.json","markdown":"https://secwatch.observer/filing/0000950103-24-005064.md","text":"https://secwatch.observer/filing/0000950103-24-005064.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1771910/000095010324005064/0000950103-24-005064-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1771910/000095010324005064/dp209553_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T01:01:09.624552+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}